Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilovertamab plus ibrutinib in relapsed/refractory mantle cell lymphoma
NCT05431179Phase 3Withdrawn
- Sponsor
- Oncternal Therapeutics
- Start
- Mar 2023
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of cirmtuzumab in mantle cell lymphoma (MCL) (3 arms), sponsored by Oncternal Therapeutics. Primary endpoint: Progression-Free Survival at 2 years. Planned start Mar 2023; status: withdrawn.
02
Drugs
cirmtuzumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05431179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431179.